<DOC>
	<DOCNO>NCT00298896</DOCNO>
	<brief_summary>The purpose study evaluate objective tumor response rate SNS-595 patient small cell lung cancer ( SCLC ) .</brief_summary>
	<brief_title>Safety Efficacy Clinical Study SNS-595 Patients With Advanced Small Cell Lung Cancer</brief_title>
	<detailed_description>Other objective study assess safety , survival rate , best response , time disease progression , duration tumor response , explore several potential biomarkers see level change administration SNS-595 .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<criteria>Able understand willing sign write informed consent document Patients recurrent refractory SCLC require secondline chemotherapy previously receive firstline chemotherapy Measurable disease Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 , 1 , 2 Brain metastasis may include patient neurologically stable steroid anticonvulsant least 4 week prior Cycle 1 Day 0 Laboratory value within normal reasonable reference range specify protocol Prior exposure SNS595 Pregnant breastfeed Women childbearing potential , male partner woman childbearing potential , unwilling use approve , effective mean contraception accord institution 's standard Other active malignancy malignancy within past 12 month , nonmelanoma skin cancer , cervical intraepithelial neoplasia , prostatic intraepithelial neoplasia Qwave myocardial infarction cerebrovascular accident/transient ischemic attack ( TIA ) within 6 month first SNS595 dose Thromboembolic event ( deep vein thrombosis pulmonary embolus ) within 28 day first SNS595 dose Requires kidney dialysis ( hemodialysis peritoneal ) Prior chemotherapy , investigational agent , radiation therapy within 28 day Cycle 1 Day 0 ; however , nitrosoureas , mitomycin C , therapeutic monoclonal antibody permit least 42 day Cycle 1 Day 0 In patient toxicity cause prior cancer therapy , toxicity must return less equal Grade 1 , exception alopecia . Prior pelvic radiation therapy radiation great 25 % bone marrow reserve ; radiation brain permit 28 day first SNS595 dose , long patient require treatment corticosteroid symptom control relate brain metastasis . Any medical , psychological , social condition , opinion Principal Investigator , would contraindicate patient 's participation clinical trial due safety compliance study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Lung</keyword>
	<keyword>Squamous Cell</keyword>
	<keyword>Small Cell</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Cancer</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
</DOC>